tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Digestive System Fistula D016154 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Peroneal Neuropathies D020427 1 associated lipids
Poxviridae Infections D011213 1 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Lacerations D022125 1 associated lipids
Megacolon, Toxic D008532 1 associated lipids
Tinea Capitis D014006 1 associated lipids
Polyomavirus Infections D027601 1 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Rheumatoid Nodule D012218 1 associated lipids
Hernia, Ventral D006555 1 associated lipids
Hepatitis, Autoimmune D019693 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Apraxias D001072 1 associated lipids
Hypertensive Encephalopathy D020343 1 associated lipids
Hearing Loss, Bilateral D006312 1 associated lipids
Nocturia D053158 1 associated lipids
Echinostomiasis D004451 1 associated lipids
Multiple Endocrine Neoplasia Type 2a D018813 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Nephritis, Hereditary D009394 1 associated lipids
Mastocytosis, Cutaneous D034701 1 associated lipids
Pancreatitis, Graft D055589 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Rectal Diseases D012002 1 associated lipids
Citrullinemia D020159 1 associated lipids
Pulmonary Veno-Occlusive Disease D011668 1 associated lipids
Sweet Syndrome D016463 1 associated lipids
Optic Neuritis D009902 1 associated lipids
Granuloma Annulare D016460 1 associated lipids
Paraneoplastic Syndromes, Nervous System D020361 1 associated lipids
Intestinal Fistula D007412 1 associated lipids
Facial Nerve Injuries D020220 1 associated lipids
Intertrigo D007402 1 associated lipids
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Central Nervous System Viral Diseases D020805 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Mediastinal Emphysema D008478 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Eye Infections, Viral D015828 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Lymphocele D008210 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Malacoplakia D008287 1 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Lichen Nitidus D017513 1 associated lipids
Lichenoid Eruptions D017512 1 associated lipids
Meningitis, Cryptococcal D016919 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Cutis Laxa D003483 1 associated lipids
Invasive Pulmonary Aspergillosis D055744 1 associated lipids
Intestinal Volvulus D045822 1 associated lipids
Hand Injuries D006230 1 associated lipids
Beckwith-Wiedemann Syndrome D001506 1 associated lipids
Eye Diseases, Hereditary D015785 1 associated lipids
Feline Infectious Peritonitis D016766 1 associated lipids
End Stage Liver Disease D058625 1 associated lipids
Nocturnal Myoclonus Syndrome D020189 1 associated lipids
Uveomeningoencephalitic Syndrome D014607 1 associated lipids
Myelitis D009187 1 associated lipids
IgG Deficiency D017099 1 associated lipids
Deltaretrovirus Infections D006800 1 associated lipids
Hepatopulmonary Syndrome D020065 1 associated lipids
Herpes Labialis D006560 1 associated lipids
Polymyositis D017285 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Rotavirus Infections D012400 1 associated lipids
Netherton Syndrome D056770 1 associated lipids
Pseudohypoaldosteronism D011546 1 associated lipids
Dendritic Cell Sarcoma, Interdigitating D054739 1 associated lipids
Intussusception D007443 1 associated lipids
Thrombotic Microangiopathies D057049 1 associated lipids
Autoimmune Diseases of the Nervous System D020274 1 associated lipids
Lupus Erythematosus, Discoid D008179 1 associated lipids
Lymphocytic Choriomeningitis D008216 1 associated lipids
Erythroplasia D004919 1 associated lipids
Hepatic Veno-Occlusive Disease D006504 1 associated lipids
West Nile Fever D014901 1 associated lipids
Hypoalbuminemia D034141 1 associated lipids
Arm Injuries D001134 1 associated lipids
Primary Graft Dysfunction D055031 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Epididymitis D004823 1 associated lipids
Pruritus Vulvae D011539 1 associated lipids
Central Serous Chorioretinopathy D056833 1 associated lipids
Feline Acquired Immunodeficiency Syndrome D016181 1 associated lipids
Budd-Chiari Syndrome D006502 1 associated lipids
AIDS-Associated Nephropathy D016263 1 associated lipids
Oral Ulcer D019226 1 associated lipids
Epidermolysis Bullosa Dystrophica D016108 1 associated lipids
Mutism D009155 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Lauzurica R et al. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus. 2007 Transplant. Proc. pmid:17889127
Ramos-Cebrián M et al. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. 2007 Transplant. Proc. pmid:17889154
Miura S et al. Long-term results of spousal renal donor transplants with donor-specific blood transfusions. 2001 Nov-Dec Transplant. Proc. pmid:11750463
Sato S et al. Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. 1998 Transplant. Proc. pmid:9636517
Pérez-Flores I et al. Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients. 2009 Jul-Aug Transplant. Proc. pmid:19715845
García Meseguer C et al. Anti-HLA antibodies posttransplantation in children: do we know what it means? 2009 Jul-Aug Transplant. Proc. pmid:19715846
Tsugita M et al. Hepatocytes or liver nonparenchymal cells plus FK 506 prolong liver xenograft survival. 1994 Transplant. Proc. pmid:7527969
Okamoto M et al. Beneficial effect of multiple drug therapy including tacrolimus in clinical renal transplantation. 2000 Transplant. Proc. pmid:11119905
Kuroki H et al. Effect of FK 506 and donor-specific blood transfusion on the rat composite tissue limb allograft and the mechanism of long-term graft survival. 1993 Transplant. Proc. pmid:7679833
Tanabe K et al. Malabsorption of tacrolimus in kidney transplant recipients: a Japanese single center experience. 2000 Transplant. Proc. pmid:11119906
Azhderian EM et al. Nucleus associated FK 506 binding proteins with potential relevance to FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7679834
Machida M et al. Effect of temperature and hematocrit on plasma concentration of FK 506. 1991 Transplant. Proc. pmid:1721266
Kawauchi M et al. Plasma level of FK 506 in newborn goats and infant baboons. 1991 Transplant. Proc. pmid:1721267
Ko S et al. Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation. 1996 Transplant. Proc. pmid:8623229
Ruiz MC et al. Effect of early versus delayed calcineurin inhibitor treatment on delayed graft function. 2003 Transplant. Proc. pmid:12644096
Vilalta R et al. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation. 2003 Transplant. Proc. pmid:12644102
Monden M et al. A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates. 1990 Transplant. Proc. pmid:1689904
Roman A et al. Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. 2002 Transplant. Proc. pmid:11959227
Morell Ginestà M et al. Histology and immunopathology of heart and liver xenografts under low-dose tacrolimus. 2002 Transplant. Proc. pmid:11959305
Abe M et al. Successful prednisone withdrawal after living-related liver transplantation. 1998 Transplant. Proc. pmid:9636584
Klupp J et al. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. 1998 Transplant. Proc. pmid:9636585
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunologic risk". 2000 Transplant. Proc. pmid:11120281
Stratta RJ et al. FK 506 induction and rescue therapy in pancreas transplant recipients. 1996 Transplant. Proc. pmid:8623492
Woodle ES et al. Corticosteroid withdrawal under tacrolimus primary and rescue therapy in renal transplantation: the Chicago experience. 1999 Transplant. Proc. pmid:10576053
O'Neill EA et al. The FK 506-sensitive nature of the interleukin-2 promoter is derived from a specific array of multiple regulatory elements. 1991 Transplant. Proc. pmid:1721298
Alessiani M et al. Total orthotopic small bowel transplantation in swine under FK 506. 1994 Transplant. Proc. pmid:7518148
Tada H et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. 2005 Transplant. Proc. pmid:15919447
Jain A et al. FK 506 in small bowel transplant recipients: pharmacokinetics and dosing. 1994 Transplant. Proc. pmid:7518149
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Murase N et al. Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. 1995 Transplant. Proc. pmid:7533386
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Zeevi A et al. Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. 1995 Transplant. Proc. pmid:7533388
Akioka K et al. Abdominal pain is a critical complication of mycophenolate mofetil in renal transplant recipients. 2003 Transplant. Proc. pmid:12591411
Ishibashi M et al. Effect of FK 506 on generation of activated macrophages invading rejected skin allografts in rats: discrepancy of in vitro versus in vivo effects. 1991 Transplant. Proc. pmid:1721330
Kawauchi M et al. Flow cytometric analysis of lymphocyte populations in FK 506-treated newborn goats. 1991 Transplant. Proc. pmid:1721331
Oike F et al. Complete withdrawal of immunosuppression in living donor liver transplantation. 2002 Transplant. Proc. pmid:12176465
Moffatt SD et al. Comparative efficacy of liposomal FK506 with FK506. 1998 Transplant. Proc. pmid:9865297
Malyszko J et al. A possible role of hepcidin in the pathogenesis of anemia among kidney allograft recipients. 2009 Transplant. Proc. pmid:19857675
Ronchetti F et al. Intestinal damage evaluation in swine allograft small bowel through hyaluronic acid quantification. 1997 Transplant. Proc. pmid:9142293
Scantlebury VP et al. Outcome of kidney transplantation in African-Americans using tacrolimus. 1997 Transplant. Proc. pmid:9414906
Forgacs B et al. Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. 2005 Transplant. Proc. pmid:15919502
Rifai K et al. Severe hearing loss after liver transplantation. 2005 Transplant. Proc. pmid:15919504
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
McCauley J et al. Renal transplantation under FK 506 in patients with previous loss of renal function due to hemolytic uremic syndrome. 1991 Transplant. Proc. pmid:1721362
Zeevi A et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. 1991 Transplant. Proc. pmid:1703341
Sánchez-Fructuoso AI et al. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors. 2003 Transplant. Proc. pmid:12962759
Martin Garcia D et al. Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications. 2003 Transplant. Proc. pmid:12962761
Miyazawa H et al. Graft immunomodulation by donor irradiation and recipient-specific bone marrow cells in rat small bowel transplantation. 2002 Transplant. Proc. pmid:12072357
Coupes BM et al. Tacrolimus monotherapy in renal transplantation: four-year data. 2002 Transplant. Proc. pmid:12176506
Sonnenday CJ et al. Preemptive therapy with plasmapheresis/intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. 2002 Transplant. Proc. pmid:12176507
Deuse T et al. Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection? 2007 Transplant. Proc. pmid:17362784
Jeong HJ et al. Vascular endothelin, TGF-beta, and PDGF expression in FK506 nephrotoxicity of rats. 1998 Transplant. Proc. pmid:9838576
Yura H et al. Development of a macromolecular prodrug of FK506: I. Synthesis of FK506-dextran conjugate. 1998 Transplant. Proc. pmid:9838577
Lohmann R et al. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083151
Kato T et al. Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083158
Cho WH et al. Basiliximab does not reduce the early rejection incidence in high-risk kidney recipients under tacrolimus-based immunosuppression. 2008 Transplant. Proc. pmid:18790201
Misao T et al. Effect of donor splenocyte transfusion with a simultaneous single injection of tacrolimus on lung allografts. 1997 Feb-Mar Transplant. Proc. pmid:9123153
Morozumi K et al. Electron-microscopic peritubular capillary lesion is a specific and useful diagnostic indicator for chronic rejection of renal allografts showing less specific morphologic lesions in the cyclosporine era. 1997 Feb-Mar Transplant. Proc. pmid:9123167
Gudas VM et al. Comparison of the immunosuppressive and toxic effects of FK506 and cyclosporine in xenograft recipients. 1989 Transplant. Proc. pmid:2468211
Carroll PB et al. FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. 1991 Transplant. Proc. pmid:1721396
Uchida J et al. Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. 2012 Transplant. Proc. pmid:22310596
Toraishi T et al. Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report. 2012 Transplant. Proc. pmid:22310597
Hesse CJ et al. The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation. 2001 Transplant. Proc. pmid:11377487
Uchida K et al. Usefulness of monitoring of AUC(0-4h) during the induction period of immunosuppressive therapy with tacrolimus after renal transplantation. 2002 Transplant. Proc. pmid:12176556
Wu MS et al. Cyclosporine, but not FK506 and rapamycin, enhances Na(+)-K(+)-CL- cotransport activity in cultured medullary thick ascending limb cells. 1999 Feb-Mar Transplant. Proc. pmid:10083527
Takahashi Y et al. Pharmacokinetic Profile of Twice- and Once-daily Tacrolimus in Pediatric Kidney Transplant Recipients. Transplant. Proc. pmid:28104153
Lemahieu WP et al. Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. 2005 Transplant. Proc. pmid:15964336
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Langrehr JM et al. Indefinite small bowel allograft survival after limited immunosuppressive therapy is not due to specific hyporesponsiveness. 1991 Transplant. Proc. pmid:1721425
Zou XM et al. Immunosuppressive effect of FK506 on orthotopic liver and small bowel xenotransplantation (xenoOLTx and SBTx). 1996 Transplant. Proc. pmid:8658729
Takeda Y et al. Effect of FK 506 on the survival of rat small bowel allografts. 1991 Transplant. Proc. pmid:1721426
Kokado Y et al. Hypertension in renal transplant recipients and its effect on long-term renal allograft survival. 1996 Transplant. Proc. pmid:8658802
Honbo T et al. The oral dosage form of FK-506. 1987 Transplant. Proc. pmid:2445068
Holt DW et al. Therapeutic monitoring of sirolimus: its contribution to optimal prescription. 2003 Transplant. Proc. pmid:12742490
Tamura K et al. A highly sensitive method to assay FK-506 levels in plasma. 1987 Transplant. Proc. pmid:2445069
Trotter JF Sirolimus in liver transplantation. 2003 Transplant. Proc. pmid:12742496
Ojogho ON et al. Mycophenolate mofetil without antibody induction in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12176641
Moray G et al. Comparison of histidine-tryptophan-ketoglutarate and University of Wisconsin in living-donor liver transplantation. 2006 Transplant. Proc. pmid:17175334
Nojima M et al. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function. Transplant. Proc. pmid:28104155
Quiroga I et al. Differential homocysteine levels in renal transplant patients receiving neoral versus tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267261
Timmermann W et al. Noninvasive videomicroscopic monitoring of rat small bowel rejection. 1998 Transplant. Proc. pmid:9745537
Yonan NA et al. Tracheal allograft transplantation in rats: the role of immunosuppressive agents in development of obliterative airway disease. 1998 Transplant. Proc. pmid:9723443
Laftavi MR et al. The role of antibiotic prophylaxis in the new era of immunosuppression. 2011 Transplant. Proc. pmid:21440753
Percy C et al. Impact of Acute Infection Requiring Hospitalization on Tacrolimus Blood Levels in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:29149962
Krämer BK et al. Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. 2017 Transplant. Proc. pmid:29149958
Kupferman JC et al. Activation of the renal renin-angiotensin system by cyclosporine A and FK 506 in the rat. 1994 Transplant. Proc. pmid:7524224
Roat MI et al. Treatment of Cogan's syndrome with FK 506: a case report. 1991 Transplant. Proc. pmid:1721457
Kelley M et al. Change in oral absorption of tacrolimus in a liver transplant recipient after reversal of jejunoileal bypass: case report. 2005 Transplant. Proc. pmid:16213338
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Ochiai T et al. Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat. 1987 Transplant. Proc. pmid:2484094
McCauley J et al. Long-term lipid metabolism in combined kidney-pancreas transplant recipients under tacrolimus immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267475
Hashi S et al. Assessment of four methodologies (microparticle enzyme immunoassay, chemiluminescent enzyme immunoassay, affinity column-mediated immunoassay, and flow injection assay-tandem mass spectrometry) for measuring tacrolimus blood concentration in Japanese liver transplant recipients. 2014 Transplant. Proc. pmid:24767342
Lo A et al. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267477
Uemoto S et al. Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. 2014 Transplant. Proc. pmid:24767340
Pinho-Apezzato ML et al. Multiple clinical presentations of lymphoproliferative disorders in pediatric liver transplant recipients: a single-center experience. 2010 Transplant. Proc. pmid:20620519
Shullo MA et al. Elevated tacrolimus levels associated with intravenous azithromycin and ceftriaxone: a case report. 2010 Transplant. Proc. pmid:20620540
Undre NA et al. Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. 1998 Transplant. Proc. pmid:9636451
Walker RE et al. Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation. 1998 Transplant. Proc. pmid:9636452
Takaya S et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. 1991 Transplant. Proc. pmid:1703691
Hildebrandt A et al. FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. 1991 Transplant. Proc. pmid:1703694